ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1052

Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking

Sokratis Apostolidis1, Kyra Sacksith1, Bria Fulmer1, Zoe Quandt2, Mark Anderson2, Terri Laufer3 and E. John Wherry1, 1University of Pennsylvania, Philadelphia, PA, 2University of California San Francisco, San Franscisco, CA, 3University of Pennsylvania, Philadlephia, PA

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, T Cell

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1052–1081) Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The use of anti-PD-1 (aPD-1) immunotherapy has seen significant success in clinical practice, corresponding with a continued rise in clinical indications for multiple cancer diagnoses. Immune-related adverse events (irAEs) are a type of secondary autoimmune toxicities arising in the setting of cancer immunotherapy. They can cause significant morbidity and disruption of the treatment of oncologic patients. They also offer a controlled setting for dissecting the cellular and signaling networks of autoimmunity development.

Methods: To better understand irAEs in the setting of aPD-1 immunotherapy, we established a prospective, longitudinal cohort at the University of Pennsylvania enrolling patients before immunotherapy and following them for a year. We stratified the responses in two groups: patients that developed at least one irAE event (irAE+) and patients that never developed an irAE event (irAE–) during that time period.

Results: Using high-dimensional cytometry, we found that irAE+ patients had a larger increase in their activated CD4 T cells after PD-1 inhibition compared to irAE– patients. In addition, plasmablast generation following immunotherapy was higher for irAE+ patients. Using PhIP-Seq, an autoantigen screening assay, we found that irAE+ patients demonstrated robust enrichment in autoantibodies against various tissue antigens after immunotherapy with unique patterns for each patient. Finally, a large-scale proteomic analysis revealed that irAE+ patients at baseline have increased levels of circulating inflammatory mediators.

Conclusion: These results indicate that there are distinct cellular and serological imprints of irAE+ patients that reflect their heightened autoimmune reactivity and can be used to uncover the underlying pathogenic mechanism of irAEs and design predictive algorithms.


Disclosures: S. Apostolidis: None; K. Sacksith: None; B. Fulmer: None; Z. Quandt: None; M. Anderson: MedTronic, 11, Merck, 11; T. Laufer: None; E. Wherry: Arsenal Biosciences, 12, Founder, Danger Bio, 1, 12, Founder, Janssen, 1, Marengo, 1, Pluto Immunotherapeutics, 1, Related Sciences, 1, Rubius Therapeutics, 1, Surface Oncology, 1, 12, Founder, Synthekine, 1.

To cite this abstract in AMA style:

Apostolidis S, Sacksith K, Fulmer B, Quandt Z, Anderson M, Laufer T, Wherry E. Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/unique-cellular-and-autoantibody-signatures-in-patients-with-iraes-revealed-by-longitudinal-immune-tracking/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unique-cellular-and-autoantibody-signatures-in-patients-with-iraes-revealed-by-longitudinal-immune-tracking/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology